stockrow
Saturday 7 November 2026
Export CLOV’s income statement to Excel — free account
Clover Health Investments, Corp.
CLOV Healthcare Healthcare Plans
Clover Health Investments, Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, up 40.3% from fiscal 2024.
- Revenue
- +52.9%
- EPS
- +350.0%
- Free cash flow
- +508.9%
Quarter to September 2026, against a year earlier
4.82
0.34
+7.59%
Follow CLOV
Alert me
| Sep '26 From the 10-Q filed 6 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.84 | 1.11 | 0.42 | 0.63 | |
P/FCF ratio |
17.32 | 37.01 | 16.85 | 0.00 | |
P/Operating CF |
32.56 | 109.05 | 8.52 | (17.65) | |
P/B ratio |
5.86 | 7.30 | 2.71 | 3.90 | |
Price to Tangible BV |
5.91 | 7.36 | 2.73 | 3.94 | |
EV/Sales |
0.76 | 1.02 | 0.33 | 0.57 | |
EV/EBITDA |
162.36 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
15.30 | 32.78 | 12.87 | (16.50) | |
EV/FCF |
15.65 | 34.03 | 13.51 | (16.01) | |
Quick Ratio |
0.28 | 0.98 | 0.82 | 1.03 | |
Current Ratio |
1.55 | 1.50 | 1.33 | 1.47 | |
Net Debt/EBITDA |
0.00 | (8.64) | (7.43) | 2.43 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
4.17 | 3.82 | 3.45 | 3.43 | |
Operating CF/Net income |
10.94 | 0.90 | 3.95 | 1.38 | |
Capex/Depreciation |
(5.38) | (5.01) | (11.54) | 7.37 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 16.74% | 17.58% | 25.24% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.01 | |
Share Based Compensation of Revenue |
1.06% | 1.22% | 1.64% | 5.11% | |
Graham Net Nets |
0.08 | 0.05 | 0.10 | 0.06 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1.16%) | (0.95%) | (6.82%) | (7.34%) | |
Free Cash Flow Yield |
5.77% | 2.70% | 5.93% | (5.73%) | |
Revenue per Share |
1.43 | 1.42 | 1.43 | 0.95 | |
Operating CF per Share |
0.13 | 0.05 | 0.21 | (0.13) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.13 | 0.05 | 0.21 | (0.13) | |
Cash per Share |
0.00 | 0.46 | 0.39 | 0.23 | |
Shareholders Equity per Share |
0.74 | 0.72 | 0.65 | 0.60 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.74 | 0.72 | 0.65 | 0.60 | |
Free Cash Flow |
69.48 | 24.51 | 107.04 | (68.75) | |
Working Capital |
189.16 | 162.12 | 111.44 | 99.03 | |
Capital Expenditures |
(0.90) | (0.68) | (0.85) | (0.60) | |
Net Current Asset Value |
172.25 | 141.38 | 89.72 | 75.55 | |
EV/EBIT |
166.22 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
184.02 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
76.53 | 60.01 | 63.50 | 73.20 | |
Average Payables |
33.38 | 34.68 | 34.86 | 35.39 | |
Average Assets |
656.67 | 647.66 | 640.72 | 560.88 | |
Average Common Equity |
365.90 | 360.22 | 337.75 | 324.92 |
Columns are period end dates · fundamentals updated 6 Nov 2026